Linkedin X-twitter Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Center, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, June 9, 2026, 1:00–2:00 PM ET
In this webinar, we will examine how immune recognition after allogeneic HCT can influence leukemia relapse and disease progression. The session will highlight the clinical relevance of HLA loss of heterozygosity (LOH), approaches used for its detection, and how LOH findings may support transplant strategies, including considerations for donor selection in subsequent transplantation.

Webinar presenter Alberto Cardoso Martins Lima, PhD, Clinical consulting scientist in histocompatibility,
specializing in allogeneic hematopoietic cell transplantation (HCT) at IGEN/AFIP São Paulo and CHC/UFPR in Curitiba, Brazil

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenter Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

CAP TODAY

Early Lyme disease detection

June 2023—Zeus Scientific has introduced the Zeus Borrelia Modified Two-Tiered Testing (MTTT) algorithm, an FDA-cleared all-ELISA algorithm designed to improve the detection of early Lyme disease by up to 30 percent compared with the standard two-tiered testing algorithm. It replaces a second-tier immunoblot with a second Zeus ELISA methodology to provide additional supportive evidence of infection. The company offers two algorithms: Zeus Borrelia MTTT-1 uses the Zeus ELISA Borrelia VlsE1/pepC10 IgG/IgM test system as a first-tier test followed by the Zeus B. burgdorferi IgG/IgM test system; Zeus Borrelia MTTT-2 uses the Zeus ELISA Borrelia VlsE1/pepC10 IgG/IgM test system as a first-tier test followed by the Zeus B. burgdorferi IgG test system and Zeus B. burgdorferi IgM test system.

 

Trane Technologies acquires Helmer Scientific

June 2023—Trane Technologies has acquired Helmer Scientific. Trane says the acquisition will broaden its capabilities in precision temperature control and its existing portfolio of life science solutions under the Farrar brand. Trane will leverage its operating system and expertise in sustainability, services, worldwide distribution, and commercialization to accelerate Helmer’s continued growth.

 

BD gets clearance for MRSA diagnostics AI software

June 2023—BD received FDA 510(k) clearance for the BD Kiestra methicillin-resistant Staphylococcus aureus imaging application, which uses artificial intelligence to automate the task of inspecting Petri dishes to determine if there is bacterial growth. The application can evaluate single specimens or group together a large volume of plates with nonsignificant growth for batch review and release negative results. It uses AI algorithms to look for specific culture characteristics on the BBL Chromagar MRSA II plate. Based on that information and analysis by BD Synapsys informatics, plate images are automatically organized and sorted into meaningful worklists, the company says.

 

Quansys Biosciences bovine-specific ELISAs

June 2023—Quansys Biosciences has developed Q-Plex Bovine Cytokine Panel 1 (5-plex), an ELISA kit that can measure five levels of bovine and African water buffalo cytokines in plasma, serum, and cell culture supernatants. Each kit contains a 96-well plate featuring the relevant biomarker panel in each well and all reagents required to perform testing.

 

Verichem calibration verifiers for cholinesterase testing

June 2023—Verichem Laboratories offers multilevel calibration verification materials for cholinesterase activity as part of its liquid-stable and ready-to-use Enzyme ER Verifier kit. The verifiers are designed to include at least one concentration level of enzyme activity within the normal range and intended to be treated as patient specimens. The material’s protein balance, pH, and ion content are constant across concentration levels. The kit material also contains multilevel assigned activities for alanine aminotransferase, alkaline phosphatase, alpha-amylase, aspartate aminotransferase, creatine phosphokinase, gamma-glutamyl transferase, lactate dehydrogenase, and lipase. Each kit has 5 mL of material for each of the six levels and a shelf-life and open-vial stability of 18 months.

 

Labcorp gets exclusive license for Proteomedix prostate cancer test

June 2023—Proteomedix (Schlieren, Switzerland) announced an exclusive license agreement in which Labcorp will develop and commercialize its Proclarix prostate specific antigen test in the United States. Proclarix is performed using the same blood sample as a PSA test and is designed to help determine the risk of clinically significant prostate cancer for men who have an elevated total PSA and a digital rectal examination finding that indicates elevated prostate volume but who are not suspected of having cancer.

 

FDA clears Panther Fusion SARS-CoV-2, flu, RSV assay

June 2023—Hologic announced the FDA has granted 510(k) clearance for its Panther Fusion SARS-CoV-2/Flu A/B/RSV assay. This molecular diagnostic test, previously under EUA, detects and differentiates SARS-CoV-2, influenza A and B, and respiratory syncytial virus. It runs on the Panther Fusion system, which provides initial results in about three hours and can process more than 1,000 tests in 24 hours.

 

Beckman Coulter unveils DxI 9000 Access

June 2023—Beckman Coulter unveiled its DxI 9000 Access immunoassay analyzer. The analyzer can run up to 215 tests per hour per square meter and does not require daily maintenance; its weekly maintenance time is less than 15 minutes. It is available in most countries.

 

Randox introduces PSA and BNP control

June 2023—Randox Labs has released two new products, a prostate-specific antigen and brain natriuretic peptide control. The liquid-frozen PSA is manufactured using human serum and has an open-vial stability of 30 days at 2°–8°C and a shelf life of one year from the date of manufacture. The control is optimized for use with Roche systems but is also suitable for use across a variety of other platforms, the company says.

 

From the President’s Desk

June 2023—I embarked this year on my first international travel as president of the CAP. Due to limitations from the pandemic, I haven’t been able to do as much of this as some of my predecessors, but happily this year we seem to be finally coming out of the worst of it.

 

MARKETPLACE

TRENDING